Posters

Treatment of macular edema associated with branch retinal vein occlusion with dexamethasone intravitreal implant

Poster Details

First Author: T.Zimina UKRAINE

Co Author(s):    N. Goncharova   E. Shkil   F. Novakova        

Abstract Details

Purpose:

To present and analyze results of dexamethasone 0,7 mg sustained-release intravitreal implant (Ozurdex; Allergan, Inc, Irvine, CA) in patients with macular edema associated with branch retinal vein occlusion (BRVO).

Setting:

Ophthalmology Department, Kharkov Medical Academy of Postgraduate Education, Ukraine

Methods:

Two adult patients (2 eyes) with macular edema associated with BRVO were assigned to receive dexamethasone 0,7 mg sustained - release intravitreal implant. Assessment of visual acuity changes was the percentage of patients gaining of best-corrected visual acuity (BCVA), the central retinal thickness (CRT) measured by optical coherence tomography (OCT), we observed extent of intraocular hemorrhage, retinal vein diameter, optic nerve head swelling, tolerability of the implant and the incidence and severity of ocular or systemic adverse events. Term of observation is 4 month.

Results:

After 1, 3 and 4 months of follow-up patients gained BCVA; mean BCVA improved on 45-50%; CRT showed a mean decrease of 50-60%. Our patients experienced decreases in the extent of retinal hemorrhage, retinal vein diameter, and optic nerve head swelling at months 3 and 4. No patients experienced a severe adverse event that was attributed to Ozurdex.

Conclusions:

Ozurdex is generally well-tolerated and may improve BCVA and decrease CRT in patients with macular edema associated with BRVO. The extent of retinal hemorrhage, retinal vein diameter, and nerve swelling continued to normalize for the patients to 4 months. FINANCIAL INTEREST: NONE